Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension of GLPG1690 (ziritaxestat) in systemic sclerosis
2019-001279-34Phase 2Unknown
- Sponsor
- Galapagos NV
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ziritaxestat in systemic sclerosis (SSc), sponsored by Galapagos NV. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Status: unknown.
02
Drugs
ziritaxestat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2019-001279-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001279-34.